These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10090611)

  • 1. Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid.
    Herman J; Jongeneel V; Kuznetsov D; Coulie PG
    Tissue Antigens; 1999 Feb; 53(2):111-21. PubMed ID: 10090611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines.
    Khanna R; Burrows SR; Neisig A; Neefjes J; Moss DJ; Silins SL
    J Virol; 1997 Oct; 71(10):7429-35. PubMed ID: 9311821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
    Herman J; van der Bruggen P; Luescher IF; Mandruzzato S; Romero P; Thonnard J; Fleischhauer K; Boon T; Coulie PG
    Immunogenetics; 1996; 43(6):377-83. PubMed ID: 8606058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3.
    Fleischhauer K; Fruci D; Van Endert P; Herman J; Tanzarella S; Wallny HJ; Coulie P; Bordignon C; Traversari C
    Int J Cancer; 1996 Nov; 68(5):622-8. PubMed ID: 8938145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.
    Brichard VG; Herman J; Van Pel A; Wildmann C; Gaugler B; Wölfel T; Boon T; Lethé B
    Eur J Immunol; 1996 Jan; 26(1):224-30. PubMed ID: 8566071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain.
    Fleischhauer K; Avila D; Vilbois F; Traversari C; Bordignon C; Wallny HJ
    Tissue Antigens; 1994 Nov; 44(5):311-7. PubMed ID: 7878657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.
    Bilsborough J; Panichelli C; Duffour MT; Warnier G; Lurquin C; Schultz ES; Thielemans K; Corthals J; Boon T; van der Bruggen P
    Tissue Antigens; 2002 Jul; 60(1):16-24. PubMed ID: 12366779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allospecific T cell epitope sharing reveals extensive conservation of the antigenic features of peptide ligands among HLA-B27 subtypes differentially associated with spondyloarthritis.
    Montserrat V; Martí M; López de Castro JA
    J Immunol; 2003 Jun; 170(11):5778-85. PubMed ID: 12759462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma-associated gene peptides by HLA-A1, HLA-A29, and HLA-B44.
    Luescher IF; Romero P; Kuznetsov D; Rimoldi D; Coulie P; Cerottini JC; Jongeneel CV
    J Biol Chem; 1996 May; 271(21):12463-71. PubMed ID: 8647853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population.
    DiBrino M; Parker KC; Margulies DH; Shiloach J; Turner RV; Biddison WE; Coligan JE
    Biochemistry; 1995 Aug; 34(32):10130-8. PubMed ID: 7543776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403.
    Terakura S; Murata M; Warren EH; Sette A; Sidney J; Naoe T; Riddell SR
    Transplantation; 2007 May; 83(9):1242-8. PubMed ID: 17496542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
    Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
    Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition among peptides in melanoma vaccines for binding to MHC molecules.
    Thompson LW; Garbee CF; Hibbitts S; Brinckerhoff LH; Pierce RA; Chianese-Bullock KA; Deacon DH; Engelhard VH; Slingluff CL
    J Immunother; 2004; 27(6):425-31. PubMed ID: 15534486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.
    Chiari R; Foury F; De Plaen E; Baurain JF; Thonnard J; Coulie PG
    Cancer Res; 1999 Nov; 59(22):5785-92. PubMed ID: 10582700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: implications for allograft rejection.
    Ely LK; Green KJ; Beddoe T; Clements CS; Miles JJ; Bottomley SP; Zernich D; Kjer-Nielsen L; Purcell AW; McCluskey J; Rossjohn J; Burrows SR
    J Immunol; 2005 May; 174(9):5593-601. PubMed ID: 15843558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation.
    Hahn YS; Hahn CS; Braciale TJ
    Immunol Cell Biol; 1996 Oct; 74(5):394-400. PubMed ID: 8912001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-B44 subtyping in the Catalan population using reference strand mediated conformation analysis. Implications for the selection of unrelated bone marrow donors.
    Gallardo D; Aróstegui JI; Rodríguez-Luaces M; Querol S; González JR; García-López J; Grañena A
    Tissue Antigens; 2000 Aug; 56(2):173-7. PubMed ID: 11019921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype.
    Hillen N; Mester G; Lemmel C; Weinzierl AO; Müller M; Wernet D; Hennenlotter J; Stenzl A; Rammensee HG; Stevanović S
    Eur J Immunol; 2008 Nov; 38(11):2993-3003. PubMed ID: 18991276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.